Everything below concerns tripeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-21. Numbers and descriptions here follow the published literature rather than marketing material.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
The sequence carries three residues in the order glycine, histidine, lysine, which places a small, flexible chain around a single metal centre. Compared with larger copper-binding proteins, the complex is compact and its coordination chemistry can be reproduced with synthetic peptide in a laboratory. Published structural work agrees on the nitrogen donor set but differs in the exact geometry assigned under some conditions, so the arrangement is best treated as well characterised in outline rather than fixed in every detail.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide was isolated from human plasma in the early 1970s by Loren Pickart, who observed that a plasma fraction from young donors stimulated growth in cultured liver cells. The copper-bound form is abbreviated GHK-Cu, while the metal-free peptide is written simply as GHK. In the research literature the complex also appears as copper tripeptide-1 and as glycyl-histidyl-lysine copper complex.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Laboratory studies describe GHK-Cu as a source of copper that cells can take up, with reported effects on collagen, elastin, and glycosaminoglycan synthesis in cultured fibroblasts. The peptide also appears in wound-repair research, where it is linked to the activity of matrix metalloproteinases and their inhibitors. These observations come largely from cell and animal models. How directly the complex controls any single pathway in intact human skin remains an open question, and reported effects depend on concentration, vehicle, and exposure time.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II)-tripeptide complex | One peptide ligand with one coordinated metal centre |
| Peptide sequence | Gly-His-Lys | Three residues written in one-letter notation |
| Free peptide mass | 340.4 g/mol | Metal-free GHK; the complex has a higher mass |
| Appearance | Blue to violet solid or solution | Colour originates from copper d orbital transitions |
| Storage | Desiccated, -20 °C, protected from light | Dry powder is more stable than dissolved material |
Copper content is measured separately, since a peptide assay alone does not report the metal-to-peptide ratio. Elemental techniques such as inductively coupled plasma optical emission spectroscopy quantify copper after acid digestion of the sample. The result is compared with the theoretical value for a one-to-one complex, and a shortfall indicates free peptide or partial dissociation. Suppliers differ in how they state purity, as some quote peptide content and others quote the whole complex. A defined stoichiometry therefore requires both a peptide assay and a copper assay.
Solid GHK-Cu is usually supplied as a lyophilized powder and is kept cold and dry. Moisture, light, and repeated temperature cycling shorten its useful life in the laboratory. In aqueous solution the complex undergoes slow hydrolysis of the peptide backbone and gradual loss of coordinated copper. Buffers containing strong chelators, such as EDTA, compete for the metal and strip it from the peptide. Working solutions are therefore prepared shortly before use, and leftover liquid is not returned to the stock container.
Dry material is typically held at low temperature, often around minus twenty degrees Celsius, and protected from moisture and light. Copper complexes can release their metal ion under acidic conditions or in the presence of competing chelators. Hydrolysis of the peptide backbone is a slower but real pathway, and the histidine residue is susceptible to oxidation over long periods. Stability statements therefore depend on formulation, pH, and container, and they should be read as conditional rather than absolute.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Copper content is measured separately by techniques such as inductively coupled plasma mass spectrometry or atomic absorption. Amino acid analysis confirms the peptide sequence after hydrolysis. Because the metal and the peptide can be quantified independently, a complete certificate of analysis normally reports both values rather than a single purity figure. This separation of measurements is important when comparing suppliers.
Solid GHK-Cu appears as a blue to blue-violet powder, and the colour is a direct consequence of copper coordination. The complex dissolves readily in water and in many polar solvents, while the free peptide behaves differently. Solubility in nonpolar media is low, which limits its use in oil-based systems. Solutions are typically prepared fresh because the dissolved form is more exposed to hydrolysis and to loss of the metal ion than the dry powder. Working concentrations are usually low, and preparation notes often specify the solvent and the order of addition.
Analytical confirmation usually combines a separation method with a copper-specific measurement. Liquid chromatography or mass spectrometry establishes peptide identity and purity, while an elemental measurement quantifies the metal content. A frequent misconception is that any blue solution contains an intact copper peptide complex; color alone does not confirm structure, because free copper salts and degraded mixtures can also appear colored. Literature on efficacy is mixed, with in vitro findings often more dramatic than human evidence, and reviews note small sample sizes and short follow-up. Open questions include optimal concentration, skin penetration, and long-term effects.
Proposed mechanisms for copper peptide activity center on delivery of copper ions to cells and on peptide fragments acting as signaling molecules. Copper is a cofactor for enzymes involved in collagen cross-linking and antioxidant defense, and the peptide may improve its availability at target sites. Separately, the tripeptide and its breakdown products have been reported to influence gene expression in cultured fibroblasts. Much of this evidence comes from laboratory cell cultures and animal models rather than controlled human trials. The relative contribution of the copper ion and the peptide sequence is therefore not fully settled.
The same cannot be said for human bone collagen, as δ18O values in collagen seem to be impacted by drinking water, food water, and a combination of metabolic and physiological processes. δ18O values from bone minerals are essentially an averaged isotopic signature throughout the entire life of the individual. While carbon and nitrogen are used primarily to investigate the diets of ancient humans, oxygen isotopes offer insight into body water at different life stages. δ18O values are used to understand drinking behaviors, animal husbandry, and track mobility. 97 burials from the ancient Maya citadel of Tikal were studied using oxygen isotopes. Results from tooth enamel identified statistically different individuals, interpreted to be individuals from Maya lowlands, Guatemala, and potentially Mexico. Historical context combined with isotopic data from burials were used to argue that migrant individuals were a part of lower and higher social classes within Tikal. Female migrants who arrived in Tikal during Early Classic period could have been the brides of Maya elite.
In September 2017, the company announced it would acquire Rigontec, developer of a candidate to target the retinoic acid-inducible gene I pathway, for $554 million. In October 2017, the company granted the inaugural Merck-AGITG Clinical Research Fellowship in Gastro-Intestinal (GI) Cancer to David Lau, a professional in Melbourne, Australia. In June 2018, Merck acquired Viralytics, an Australian viral cancer drug company, for AUD$502 million. In 2018, Merck began the submission process for a Biologics License Application to the Food and Drug Administration under the Breakthrough Therapy Designation for an investigational vaccine, called V920, to fight the Zaire strain of the Ebola virus. In April 2019, the company acquired Immune Design for approximately $300 million, gaining access to its immunotherapy programs. It also acquired Antelliq Group for $2.4 billion, or $3.7 billion including debt. In May 2019, Merck announced it would acquire Peloton Therapeutics, developer of a HIF-2alpha inhibitor for Von Hippel–Lindau disease-associated renal cell carcinoma, for up to $2.2 billion. In June 2019, Merck announced it would acquire Tilos Therapeutics for up to $773 million. In November 2019, the company acquired Calporta, which focused on Parkinsons and Alzheimers treatments. In December 2019, Merck Animal Health acquired Vaki, an aquaculture company, from Pentair.
== Diagnostic advantages == Due to PCT's variance between microbial infections and healthy individuals, procalcitonin has become a marker to improve identification of bacterial infection and guide antibiotic therapy. The table below is a summary from Schuetz, Albrich, and Mueller, summarizing the current data of selected, relevant studies investigating PCT in different types of infections. Legend: ✓ = Moderate evidence in favor of PCT ✓✓ = Good evidence in favor of PCT ✓✓✓ = Strong evidence in favor of PCT ~ = Evidence in favor or against the use of PCT, or still undefined
White Rhodesian officers and non-commissioned officers left the colony in September and October 1939 to command units of black Africans in the west and east of the continent, with most joining the Royal West African Frontier Force (RWAFF) in the Colony of Nigeria, the Gold Coast and neighbouring colonies. The deployment of white Rhodesian officers and NCOs to command black troops from elsewhere in Africa met with favour from the military leadership and became very prevalent.
=== Recreational use === Methylergometrine is a synthetic analogue of ergometrine, a psychedelic alkaloid found in ergot, and many species of morning glory. Methylergometrine is a member of the ergoline family and chemically similar to LSD, ergine, ergometrine, and lysergic acid. According to Jonathan Ott, methylergometrine produces LSD-like psychedelic effects at doses of 2 mg and above. Clinical effectiveness of methylergometrine as a medication occurs around 200 μg, which is 10 times lower than the hallucinogenic threshold.
Sources: en.wikipedia.org
AT-121 is an experimental analgesic. It was designed to be bifunctional, acting as an agonist at both the μ-opioid receptor and the nociceptin receptor. The interaction with the nociceptin receptor is expected to block the abuse and dependence-related side effects that are typical of opioids. A study in nonhuman primates found that AT-121 has morphine-like analgesic effects, but suppressed the addictive effects.
Radon is produced by the radioactive decay of radium-226, which is found in uranium ores, phosphate rock, shales, igneous and metamorphic rocks such as granite, gneiss, and schist, and to a lesser degree, in common rocks such as limestone. Every square mile of surface soil, to a depth of 6 inches (2.6 km2 to a depth of 15 cm), contains about 1 gram of radium, which releases radon in small amounts to the atmosphere. It is estimated that 2.4 billion curies (90 EBq) of radon are released from soil annually worldwide. This is equivalent to some 15.3 kilograms (34 lb). Radon concentration can differ widely from place to place. In the open air, it ranges from 1 to 100 Bq/m3, even less (0.1 Bq/m3) above the ocean. In the United States, the average outdoor radon level is estimated to be 15 Bq/m3 (0.4 pCi/L). In caves or ventilated mines, or poorly ventilated houses, its concentration climbs to 20–2,000 Bq/m3. Radon concentration can be much higher in mining contexts. Ventilation regulations instruct to maintain radon concentration in uranium mines under the "working level", with 95th percentile levels ranging up to nearly 3 WL (546 pCi 222Rn per liter of air; 20.2 kBq/m3, measured from 1976 to 1985). The concentration in the air at the (unventilated) Gastein Healing Gallery averages 43 kBq/m3 (1.2 nCi/L) with maximal value of 160 kBq/m3 (4.3 nCi/L). Radon mostly appears with the radium/uranium series (decay chain) (222Rn), and marginally with the thorium series (220Rn).
in the above equation modulo ln(2)) of the parent and daughter, respectively, and BR is the branching ratio. In transient equilibrium, the Bateman equation cannot be simplified by assuming the daughter's half-life is negligible compared to the parent's half-life. The ratio of daughter-to-parent activity is given by:
== Teams == The FA Cup was a knockout competition with 124 teams taking part all trying to reach the final at Wembley on 3 June 2023. The competition consisted of the 92 teams from the Football League system (20 teams from the Premier League and the 72 in total from the EFL Championship, EFL League One and EFL League Two) plus the 32 surviving teams out of 640 teams from the National League System (all but eleven clubs from 5–9 and eleven replacements from tier 10 of the English football league system) that started the competition in the qualifying rounds. Qualification rounds were on a geographical basis and main competition rounds were drawn randomly usually either at the completion of the previous round or on the evening of the last televised game of a round being played depending on television broadcasting rights.
Erbium(III) oxide (also known as erbia) is the only known oxide of erbium, first isolated by Carl Gustaf Mosander in 1843, and first obtained in pure form in 1905 by Georges Urbain and Charles James. It has a cubic structure resembling the bixbyite motif. The Er3+ centers are octahedral. The formation of erbium oxide is accomplished by burning erbium metal, erbium oxalate or other oxyacid salts of erbium. Erbium oxide is insoluble in water and slightly soluble in heated mineral acids. The pink-colored compound is used as a phosphor activator and to produce infrared-absorbing glass.
Sources: en.wikipedia.org
It consists of a three-amino-acid peptide, glycine-histidine-lysine, bound to one copper(II) ion. The peptide supplies four nitrogen donor atoms, and the resulting complex is stable in neutral aqueous solution. The metal-free peptide is usually called GHK.
The three letters are the standard one-letter codes for glycine, histidine, and lysine. The suffix -Cu indicates the coordinated copper ion. Cosmetic ingredient lists often use the alternative name copper tripeptide-1 for the same complex.
No. Free GHK is the peptide alone, while GHK-Cu contains a bound copper atom. The two differ in colour, charge, and binding behaviour, so any study that measures copper delivery must state which form was used.
It is not approved as a pharmaceutical in major markets and is used mainly as a cosmetic ingredient and a laboratory reagent. Regulatory status varies by country and by the product category in which it appears. Claims about therapeutic effects should be treated separately from permitted cosmetic labeling.